Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-8bljj Total loading time: 0 Render date: 2024-06-14T21:41:45.039Z Has data issue: false hasContentIssue false

16 - Treatment approach to diffuse large B-cell lymphomas

Published online by Cambridge University Press:  10 January 2011

Sonali M. Smith
Affiliation:
The University of Chicago, Chicago, IL, USA
Julie M. Vose
Affiliation:
Section of Hematology/Oncology, Nebraska Medical Center, Omaha, NE, USA
Susan O'Brien
Affiliation:
University of Texas/MD Anderson Cancer Center, Houston
Julie M. Vose
Affiliation:
University of Nebraska Medical Center, Omaha
Hagop M. Kantarjian
Affiliation:
University of Texas/MD Anderson Cancer Center, Houston
Get access

Summary

Introduction

Non-Hodgkin lymphoma (NHL) is a heterogeneous cancer encompassing several dozen distinct clinicopathologic diseases. The incidence of NHL appears to be rising independent of the aging of the population, and NHL currently ranks as the fifth most common cancer in both men and women with 71,380 new cases in 2007 and nearly 20,000 estimated deaths. Diffuse large B-cell lymphoma (DLBCL), accounting for approximately one-third of all new cases, is both the most common histologic subtype of NHL and the prototype of aggressive lymphomas.

There are several histologic variants and clinical subtypes of DLBCL that are recognized (Figure 16.1). Histologic variants include immunoblastic, centroblastic, and anaplastic morphologies, whereas distinct clinical subtypes have included primary mediastinal large B-cell lymphoma (PMBL), intravascular large B-cell lymphoma, and primary effusion lymphoma, among others. The latter two entities occur primarily in immunocompromised hosts and are associated with human herpesvirus 8. The histologic heterogeneity of DLBCL is complicated by the recent identification of molecular heterogeneity discovered by gene expression profiling, and is discussed in more detail below with an emphasis on its prognostic potential.

In general, DLBCL is a chemosensitive disease with a substantial portion of patients achieving cure with frontline chemoimmunotherapy. Unfortunately, many patients continue to relapse and are in need of further treatment. Patients with chemosensitive disease at relapse can achieve long-term disease control with autologous stem cell transplant, but others will succumb to DLBCL. Patients with refractory disease, those who relapse following transplant, and those who are not candidates for transplantation have no true curative options and most will ultimately die of lymphoma.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

,American Cancer Society Atlanta. Cancer Facts and Figures: 2007. www.cancer.org/docroot.
Swerdlow, S, Campo, E, Harris, N, et al. (eds.) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon, France, IARC Press, 2008.Google Scholar
Jaffe, ES, Harris, NL, Stein, H, et al. (eds.) World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001.Google Scholar
Jemal, A, Siegel, R, Ward, E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.CrossRefGoogle ScholarPubMed
Levine, AM, Seneviratne, L, Espina, BM, et al. Evolving characteristics of AIDS-related lymphoma. Blood 2000;96:4084–90.Google ScholarPubMed
Altieri, A, Bermejo, JL, Hemminki, K. Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. Blood 2005;106:668–72.CrossRefGoogle ScholarPubMed
Morton, LM, Wang, SS, Cozen, W, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood 2008;112:5150–60.CrossRefGoogle ScholarPubMed
Kanungo, A, Medeiros, LJ, Abruzzo, LV, et al. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol 2006;19:25–33.CrossRefGoogle Scholar
Gouill, S, Talmant, P, Touzeau, C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 2007;92:1335–42.CrossRefGoogle Scholar
Cheson, BD, Horning, SJ, Coiffier, B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.CrossRefGoogle ScholarPubMed
Cheson, BD, Pfistner, B, Juweid, ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–86.CrossRefGoogle ScholarPubMed
Haioun, C, Itti, E, Rahmouni, A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376–81.CrossRefGoogle ScholarPubMed
Kostakoglu, L, Goldsmith, SJ, Leonard, JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006;107:2678–87.CrossRefGoogle ScholarPubMed
Ng, AP, Wirth, A, Seymour, JF, et al. Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. Leuk Lymphoma 2007;48:596–600.CrossRefGoogle Scholar
Seam, P, Juweid, ME, Cheson, BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007;110:3507–16.CrossRefGoogle ScholarPubMed
,The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987–94.CrossRefGoogle Scholar
Sehn, LH, Berry, B, Chhanabhai, M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–61.CrossRefGoogle Scholar
Alizadeh, AA, Eisen, MB, Davis, RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–11.CrossRefGoogle ScholarPubMed
Rosenwald, A, Wright, G, Chan, WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–47.CrossRefGoogle ScholarPubMed
Shipp, MA, Ross, KN, Tamayo, P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68–74.CrossRefGoogle ScholarPubMed
Lossos, IS, Czerwinski, DK, Alizadeh, AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350:1828–37.CrossRefGoogle ScholarPubMed
Chang, CC, McClintock, S, Cleveland, RP, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004;28:464–70.CrossRefGoogle ScholarPubMed
Hans, CP, Weisenburger, DD, Greiner, TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103(1):275–82.CrossRefGoogle ScholarPubMed
Malumbres, R, Chen, J, Tibshirani, R, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 2008;111:5509–14.CrossRefGoogle ScholarPubMed
Gascoyne, RD, Adomat, SA, Krajewski, S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997;90:244–51.Google ScholarPubMed
Iqbal, J, Neppalli, VT, Wright, G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006;24:961–8.CrossRefGoogle ScholarPubMed
Mounier, N, Briere, J, Gisselbrecht, C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279–84.CrossRefGoogle Scholar
Winter, JN, Weller, EA, Horning, SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006;107:4207–13.CrossRefGoogle ScholarPubMed
Natkunam, Y, Farinha, P, Hsi, ED, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 2008;26:447–54.CrossRefGoogle ScholarPubMed
Natkunam, Y, Zhao, S, Mason, DY, et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood 2007;109:1636–42.CrossRefGoogle ScholarPubMed
Spicer, J, Smith, P, Maclennan, K, et al. Long-term follow-up of patients treated with radiotherapy alone for early-stage histologically aggressive non-Hodgkin's lymphoma. Br J Cancer 2004;90:1151–5.CrossRefGoogle ScholarPubMed
Shenkier, TN, Voss, N, Fairey, R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 2002;20:197–204.CrossRefGoogle ScholarPubMed
Miller, TP, Dahlberg, S, Cassady, JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21–6.CrossRefGoogle ScholarPubMed
Ballonoff, A, Rusthoven, KE, Schwer, A, et al. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys 2008;72:1465–71.CrossRefGoogle ScholarPubMed
Miller, TP, LeBlanc, M, Spier, CM, et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial. Blood 2001;98:724a.Google Scholar
Bonnet, C, Fillet, G, Mounier, N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007;25:787–92.CrossRefGoogle ScholarPubMed
Reyes, F, Lepage, E, Ganem, G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352: 1197–205.CrossRefGoogle ScholarPubMed
Horning, SJ, Weller, E, Kim, K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004;22:3032–8.CrossRefGoogle ScholarPubMed
Pfreundschuh, M, Trumper, L, Osterborg, A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–91.CrossRefGoogle ScholarPubMed
Pfreundschuh, M, Ho, AD, Cavallin-Stahl, E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008;9:435–44.CrossRefGoogle ScholarPubMed
Persky, , Unger, JM, Spier, CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008;26:2258–63.CrossRefGoogle Scholar
Sehn, HL, Savage, KJ, Hoskins, P, et al. Limited-stage diffuse large B-cell lymphoma (DLBCL) patients with a negative PET scan following three cycles of R-CHOP can be effectively treated with abbreviated chemoimmunotherapy alone. Blood 2007;110:787a.Google Scholar
Elias, L, Portlock, CS, Rosenberg, SA. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer 1978;42:1705–10.3.0.CO;2-P>CrossRefGoogle Scholar
McKelvey, EM, Gottlieb, JA, Wilson, HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976;38:1484–93.3.0.CO;2-I>CrossRefGoogle ScholarPubMed
Fisher, RI, Gaynor, ER, Dahlberg, S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002–6.CrossRefGoogle ScholarPubMed
Cartron, G, Watier, H, Golay, J, Solal-Celigny, P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104:2635–42.CrossRefGoogle ScholarPubMed
Coiffier, B, Haioun, C, Ketterer, N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927–32.Google ScholarPubMed
Coiffier, B, Feugier, P, Mounier, N, et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. J Clin Oncol 2007;25:Abstract 8009.Google Scholar
Coiffier, B, Lepage, E, Briere, J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–42.CrossRefGoogle ScholarPubMed
Habermann, TM, Weller, EA, Morrison, VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–7.CrossRefGoogle ScholarPubMed
Feugier, P, Hoof, A, Sebban, C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117–26.CrossRefGoogle ScholarPubMed
Wilson, KS, Sehn, LH, Berry, B, et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma 2007;48:1102–9.CrossRefGoogle ScholarPubMed
Blayney, DW, LeBlanc, ML, Grogan, T, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 2003;21:2466–73.CrossRefGoogle Scholar
Portlock, CS, Qin, J, Schaindlin, P, et al. The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide. Ann Oncol 2004;15:1495–503.CrossRefGoogle ScholarPubMed
Wunderlich, A, Kloess, M, Reiser, M, et al. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2003; 14:881–93.CrossRefGoogle Scholar
Pfreundschuh, M, Trumper, L, Kloess, M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–41.CrossRefGoogle ScholarPubMed
Pfreundschuh, M, Trumper, L, Kloess, M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626–33.CrossRefGoogle ScholarPubMed
Pfreundschuh, M, Schubert, J, Ziepert, M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without intuximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–16.CrossRefGoogle Scholar
Pfreundschuh, M, Zeynalova, S, Poeschel, V, et al. Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). J Clin Oncol 2008;20 Suppl: Abstract 8508.Google Scholar
Gutierrez, M, Chabner, BA, Pearson, D, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000; 18:3633–42.CrossRefGoogle ScholarPubMed
Wilson, WH, Grossbard, ML, Pittaluga, S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002;99:2685–93.CrossRefGoogle ScholarPubMed
Garcia-Suarez, J, Banas, H, Arribas, I, et al. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. Br J Haematol 2007;136:276–85.CrossRefGoogle ScholarPubMed
Wilson, WH, Dunleavy, K, Pittaluga, S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008;26:2717–24.CrossRefGoogle ScholarPubMed
Zinzani, PL, Tani, M, Fanti, S, et al. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol 2008;19:769–73.CrossRefGoogle ScholarPubMed
Baldissera, RC, Nucci, M, Vigorito, AC, et al. Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report. Acta Haematol 2006;115:15–21.CrossRefGoogle ScholarPubMed
Kaiser, U, Uebelacker, I, Abel, U, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. J Clin Oncol 2002;20:4413–19.CrossRefGoogle ScholarPubMed
Martelli, M, Gherlinzoni, F, Renzo, A, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol 2003;21:1255–62.CrossRefGoogle ScholarPubMed
Martelli, M, Vignetti, M, Zinzani, PL, et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 1996;14:534–42.CrossRefGoogle ScholarPubMed
Verdonck, LF, Putten, WL, Hagenbeek, A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995;332:1045–51.CrossRefGoogle ScholarPubMed
Haioun, C, Lepage, E, Gisselbrecht, C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87–2 protocol–a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000;18:3025–30.CrossRefGoogle ScholarPubMed
Kluin-Nelemans, HC, Zagonel, V, Anastasopoulou, A, et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 2001;93:22–30.CrossRefGoogle ScholarPubMed
Santini, G, Salvagno, L, Leoni, P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998;16:2796–802.CrossRefGoogle ScholarPubMed
Gianni, AM, Bregni, M, Siena, S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290–7.CrossRefGoogle ScholarPubMed
Gisselbrecht, C, Lepage, E, Molina, T, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002;20:2472–9.CrossRefGoogle ScholarPubMed
Milpied, N, Deconinck, E, Gaillard, F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287–95.CrossRefGoogle ScholarPubMed
Vitolo, U, Liberati, AM, Cabras, MG, et al. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an “Intergruppo Italiano Linfomi” randomized trial. Haematologica 2005;90:793–801.Google Scholar
Strehl, J, Mey, U, Glasmacher, A, et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica 2003;88:1304–15.Google ScholarPubMed
Vose, JM, Zhang, MJ, Rowlings, PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19:406–13.CrossRefGoogle ScholarPubMed
Kewalramani, T, Zelenetz, AD, Hedrick, EE, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000;96:2399–404.Google ScholarPubMed
Rodriguez, J, Caballero, MD, Gutierrez, A, et al. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Ann Oncol 2004;15:1504–9.CrossRefGoogle Scholar
Boehme, V, Zeynalova, S, Kloess, M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma–a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007;18:149–57.CrossRefGoogle Scholar
Boehme, V, Zeynalova, S, Lengfelder, E, et al. CNS-disease in elderly patients treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of CNS events in the RICOVER-60 trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Blood 2007;110:Abstract 519.Google Scholar
Feugier, P, Virion, JM, Tilly, H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004;15:129–33.CrossRefGoogle ScholarPubMed
Haioun, C, Besson, C, Lepage, E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 2000;11:685–90.CrossRefGoogle ScholarPubMed
Besien, K, Ha, CS, Murphy, S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998;91:1178–84.Google ScholarPubMed
Hill, QA, Owen, RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006;20:319–32.CrossRefGoogle ScholarPubMed
Doolittle, ND, Abrey, , Shenkier, TN, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood 2008;111:1085–93.CrossRefGoogle ScholarPubMed
Tilly, H, Lepage, E, Coiffier, B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003;102:4284–9.CrossRefGoogle ScholarPubMed
Vose, JM, Rizzo, DJ, Tao-Wu, J, et al. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant 2004;10:116–27.CrossRefGoogle ScholarPubMed
Josting, A, Sieniawski, M, Glossmann, JP, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol 2005;16:1359–65.CrossRefGoogle ScholarPubMed
Shipp, MA, Abeloff, MD, Antman, KH, et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol 1999;17:423–9.CrossRefGoogle ScholarPubMed
Blay, J, Gomez, F, Sebban, C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998;92:3562–8.Google ScholarPubMed
Hamlin, PA, Zelenetz, AD, Kewalramani, T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:1989–96.CrossRefGoogle ScholarPubMed
Besien, K, Rodriguez, A, Tomany, S, et al. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant 2001;27:397–404.CrossRefGoogle ScholarPubMed
Costa, LJ, Micallef, IN, Inwards, DJ, et al. Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation. Bone Marrow Transplant 2008;41:715–20.CrossRefGoogle ScholarPubMed
Moskowitz, CH, Bertino, JR, Glassman, JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3776–85.CrossRefGoogle ScholarPubMed
Schot, BW, Zijlstra, JM, Sluiter, WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007;109:486–91.CrossRefGoogle ScholarPubMed
Spaepen, K, Stroobants, S, Dupont, P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1356–63.CrossRefGoogle ScholarPubMed
Svoboda, J, Andreadis, C, Elstrom, R, et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006;38:211–16.CrossRefGoogle ScholarPubMed
Crocchiolo, R, Canevari, C, Assanelli, A, et al. Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma 2008;49:727–33.CrossRefGoogle ScholarPubMed
Spaepen, K, Stroobants, S, Dupont, P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003;102:53–9.CrossRefGoogle ScholarPubMed
Moskowitz, CH, Zelenetz, AD, Kewalramani, T, et al. Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 2005;106:3383–85.CrossRefGoogle Scholar
Corazzelli, G, Russo, F, Capobianco, G, et al. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Ann Oncol 2006;17 Suppl 4:iv18–24.CrossRefGoogle ScholarPubMed
Vellenga, E, Putten, WL, van't Veer, MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008;111:537–43.CrossRefGoogle ScholarPubMed
Kewalramani, T, Zelenetz, AD, Nimer, SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684–8.CrossRefGoogle ScholarPubMed
Sieniawski, M, Staak, O, Glossmann, JP, et al. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Hematol 2007;86:107–15.CrossRefGoogle Scholar
Fenske, TS, Hari, PN, Carreras, J, et al. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant 2009;15:1455–64.CrossRefGoogle ScholarPubMed
Gisselbrecht, C, Schmitz, N, Mounier, N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: first interim analysis on 200 patients. CORAL Study. Blood 2007;110:517a.Google Scholar
Friedberg, JW, Neuberg, D, Stone, RM, et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3128–35.CrossRefGoogle ScholarPubMed
Milligan, DW, Ruiz De Elvira, MC, Kolb, HJ, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol 1999;106:1020–6.CrossRefGoogle ScholarPubMed
Vose, JM, Bierman, PJ, Enke, C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005;23:461–7.CrossRefGoogle ScholarPubMed
Vose, J, Bierman, PJ, Bociek, G, et al. Radioimmunotherapy with 131-I tositumomab enhanced survival in good prognosis relapsed and high-risk diffuse large B-cell lymphoma (DLBCL) patients receiving high-dose chemotherapy and autologous stem cell transplantation. J Clin Oncol(2007 ASCO Annual Meeting Proceedings Part 1) 2007;25(185): Abstract 8013.Google Scholar
Krishnan, A, Nademanee, A, Fung, HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008;26:90–5.CrossRefGoogle ScholarPubMed
Nademanee, A, Forman, S, Molina, A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005;106:2896–902.CrossRefGoogle ScholarPubMed
Shimoni, A, Zwas, ST, Oksman, Y, et al. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol 2007;35:534–40.CrossRefGoogle ScholarPubMed
Winter, JN, Inwards, DJ, Spies, S, et al. 90Y Ibritumomab tiuxetan (Zevalin®; 90YZ) doses calculated to deliver up to 1500 cGy to critical organs may be safely combined with high-dose BEAM and autotransplant in NHL. Blood 2006;108:330a.Google Scholar
Alousi, AM, Hosing, C, Saliba, R, et al. Zevalin®/BEAM/rituximab vs BEAM/rituximab and autologous stem cell transplantation (ASCT) for relapsed chemosensitive diffuse large B-cell lymphoma (DLBCL): impact of the IPI and PET status. Blood 2007;110:620a.Google Scholar
Kewalramani, T, Nimer, SD, Zelenetz, AD, et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003;32:673–9.CrossRefGoogle ScholarPubMed
Philip, T, Guglielmi, C, Hagenbeek, A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–5.CrossRefGoogle ScholarPubMed
Vose, JM, Bierman, PJ, Anderson, JR, et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992;80:2142–8.Google ScholarPubMed
Kline, J, Subbiah, S, Lazarus, HM, et al. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. Bone Marrow Transplant 2008;41:505–13.CrossRefGoogle ScholarPubMed
Thompson, JA, Fisher, RI, Leblanc, M, et al. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood 2008;111:4048–54.CrossRefGoogle Scholar
Khouri, IF, Saliba, RM, Hosing, C, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005;23:2240–7.CrossRefGoogle ScholarPubMed
Horwitz, SM, Negrin, RS, Blume, KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004;103:777–83.CrossRefGoogle ScholarPubMed
Lee, MY, Chiou, TJ, Hsiao, LT, et al. Rituximab therapy increased post-transplant cytomegalovirus complications in non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation. Ann Hematol 2008;87:285–9.CrossRefGoogle ScholarPubMed
Lemieux, B, Tartas, S, Traulle, C, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;33:921–3.CrossRefGoogle ScholarPubMed
Shortt, J, Spencer, A. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 2006;38:433–6.CrossRefGoogle ScholarPubMed
Faulkner, RD, Craddock, C, Byrne, JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004;103:428–34.CrossRefGoogle ScholarPubMed
Morris, E, Thomson, K, Craddock, C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004;104:3865–71.CrossRefGoogle ScholarPubMed
Robinson, SP, Goldstone, AH, Mackinnon, S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310–16.CrossRefGoogle ScholarPubMed
Peniket, AJ, Ruiz de Elvira, MC, Taghipour, G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003;31:667–78.CrossRefGoogle ScholarPubMed
Besien, KW, Lima, M, Giralt, SA, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997;19:977–82.CrossRefGoogle ScholarPubMed
Dhedin, N, Giraudier, S, Gaulard, P, et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle. Br J Haematol 1999;107:154–61.CrossRefGoogle ScholarPubMed
Doocey, RT, Toze, CL, Connors, JM, et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 2005;131:223–30.CrossRefGoogle ScholarPubMed
Rodriguez, R, Nademanee, A, Ruel, N, et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12:1326–34.CrossRefGoogle ScholarPubMed
Freytes, CO, Loberiza, FR, Rizzo, JD, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004;104:3797–803.CrossRefGoogle ScholarPubMed
Branson, K, Chopra, R, Kottaridis, PD, et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002;20:4022–31.CrossRefGoogle ScholarPubMed
Escalon, MP, Champlin, RE, Saliba, RM, et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004;22:2419–23.CrossRefGoogle ScholarPubMed
Coiffier, B, Feugier, P, Mounier, N, et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. J Clin Oncol(2007 ASCO Annual Meeting Proceedings) 2007;25(18S): Abstract 8009.Google Scholar
Lichtenstein, AK, Levine, A, Taylor, CR, et al. Primary mediastinal lymphoma in adults. Am J Med 1980;68:509–14.CrossRefGoogle ScholarPubMed
Miller, JB, Variakojis, D, Bitran, JD, et al. Diffuse histiocytic lymphoma with sclerosis: a clinicopathologic entity frequently causing superior venacaval obstruction. Cancer 1981;47:748–56.3.0.CO;2-8>CrossRefGoogle ScholarPubMed
Hamlin, PA, Portlock, CS, Straus, DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005;130:691–9.CrossRefGoogle ScholarPubMed
Todeschini, G, Secchi, S, Morra, E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004;90:372–6.CrossRefGoogle ScholarPubMed
Zinzani, PL, Martelli, M, Bertini, M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002;87:1258–64.Google ScholarPubMed
Rosenwald, A, Wright, G, Leroy, K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851–62.CrossRefGoogle ScholarPubMed
Iqbal, J, Greiner, TC, Patel, K, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 2007;21:2332–43.CrossRefGoogle ScholarPubMed
Weniger, MA, Gesk, S, Ehrlich, S, et al. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes Chromosomes Cancer 2007;46:406–15.CrossRefGoogle ScholarPubMed
Abou-Elella, AA, Weisenburger, DD, Vose, JM, et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. J Clin Oncol 1999;17:784–90.CrossRefGoogle ScholarPubMed
Cazals-Hatem, D, Lepage, E, Brice, P, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d'Etude des Lymphomes de l'Adulte”) study. Am J Surg Pathol 1996;20:877–88.CrossRefGoogle Scholar
Savage, KJ, Al-Rajhi, N, Voss, N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006;17:123–30.CrossRefGoogle Scholar
Lazzarino, M, Orlandi, E, Paulli, M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol 1997;15:1646–53.CrossRefGoogle ScholarPubMed
Nguyen, LN, Ha, CS, Hess, M, et al. The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum. Int J Radiat Oncol Biol Phys 2000;47:1281–5.CrossRefGoogle Scholar
Zinzani, PL, Martelli, M, Magagnoli, M, et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood 1999; 94:3289–93.Google ScholarPubMed
Haioun, C, Gaulard, P, Roudot-Thoraval, F, et al. Mediastinal diffuse large-cell lymphoma with sclerosis: a condition with a poor prognosis. Am J Clin Oncol 1989;12:425–9.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×